Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Saro Therapeutics
Framingham, Massachusetts, USAsarotx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Saro Therapeutics is a preclinical-stage biotechnology company focused on developing transformative tRNA-based therapies for rare genetic diseases caused by nonsense mutations. The company's primary focus is on cystic fibrosis, specifically targeting the subset of patients with Class I mutations who do not benefit from existing CFTR modulators. Their proprietary platform utilizes suppressor tRNAs to enable the read-through of premature stop codons, thereby restoring the production of full-length, functional proteins. Headquartered in the Boston area, Saro Therapeutics aims to expand its genetic medicine approach to a variety of underserved genetic disorders beyond pulmonology.
- Therapeutic areas
- Pulmonology
- Modalities
- RNA therapytRNA therapy
- Industry
- Biotech
Beyond the preview
Go deeper on Saro Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saro Therapeutics.